Protective Effect of Recombinant Staphylococcal Enterotoxin A Entrapped in Polylactic-co-glycolic Acid Microspheres Against Staphylococcus Aureus Infection

Overview

Journal Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2012 Mar 21

PMID 22429499

Citations 3

Authors

Liben Chen

Shuang Li

Zhengfang Wang

Ruilong Chang

Jingliang Su

Bo Han

Affiliations

Soon will be listed here.

Abstract

Staphylococcus aureus is an important cause of nosocomial and community-acquired infections in humans and animals, as well as the cause of mastitis in dairy cattle. Vaccines aimed at preventing S. aureus infection in bovine mastitis have been studied for many years, but have so far been unsuccessful due to the complexity of the bacteria, and the lack of suitable vaccine delivery vehicles. The current study developed an Escherichia coli protein expression system that produced a recombinant staphylococcal enterotoxin A (rSEA) encapsulated into biodegradable microparticles generated by polylactic-co-glycolic acid (PLGA) dissolved in methylene chloride and stabilized with polyvinyl acetate. Antigen loading and surface properties of the microparticles were investigated to optimize particle preparation protocols. The prepared PLGA-rSEA microspheres had a diameter of approximately 5 μm with a smooth and regular surface. The immunogenicity of the PLGA-rSEA vaccine was assessed using mice as an animal model and showed that the vaccine induced a strong humoral immune response and increased the percent survival of challenged mice and bacterial clearance. Histological analysis showed moderate impairment caused by the pathogen upon challenge afforded by immunization with PLGA-rSEA microspheres. Antibody titer in the sera of mice immunized with PLGA-rSEA microparticles was higher than in vaccinated mice with rSEA. In conclusion, the PLGA-rSEA microparticle vaccine developed here could potentially be used as a vaccine against enterotoxigenic S. aureus.

Citing Articles

Recombinant PBP2a/autolysin conjugate as PLGA-based nanovaccine induced humoral responses with opsonophagocytosis activity, and protection versus methicillin-resistant infection.

Haghighat S, Siadat S, Sepahi A, Mahdavi M Iran J Basic Med Sci. 2022; 25(4):442-450.

PMID: 35656080 PMC: 9150805. DOI: 10.22038/IJBMS.2022.59992.13303.

Evaluation of antibacterial activity induced by and Ent A in the hemolymph of .

Radwan M, Alaidaroos B, Jastaniah S, Abu El-Naga M, El-Gohary E, Barakat E Saudi J Biol Sci. 2022; 29(4):2892-2903.

PMID: 35531219 PMC: 9073143. DOI: 10.1016/j.sjbs.2022.01.025.

Prophylactic vaccine delivery systems against epidemic infectious diseases.

Pan C, Yue H, Zhu L, Ma G, Wang H Adv Drug Deliv Rev. 2021; 176:113867.

PMID: 34280513 PMC: 8285224. DOI: 10.1016/j.addr.2021.113867.

References

Saini V, Jain V, Sudheesh M, Jaganathan K, Murthy P, Kohli D . Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int J Pharm. 2011; 408(1-2):50-7. DOI: 10.1016/j.ijpharm.2011.01.045. View

Close B, Banister K, Baumans V, Bernoth E, Bromage N, Bunyan J . Recommendations for euthanasia of experimental animals: Part 2. DGXT of the European Commission. Lab Anim. 1997; 31(1):1-32. DOI: 10.1258/002367797780600297. View

Lowell G, Colleton C, Frost D, Kaminski R, Hughes M, Hatch J . Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun. 1996; 64(11):4686-93. PMC: 174432. DOI: 10.1128/iai.64.11.4686-4693.1996. View

Middleton J, Luby C, Adams D . Efficacy of vaccination against staphylococcal mastitis: a review and new data. Vet Microbiol. 2008; 134(1-2):192-8. DOI: 10.1016/j.vetmic.2008.09.053. View

Singh M, Li X, McGee J, Zamb T, Koff W, Wang C . Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine. 1997; 15(5):475-81. DOI: 10.1016/s0264-410x(97)00225-9. View

Pereira U, Oliveira D, Mesquita L, Costa G, Pereira L . Efficacy of Staphylococcus aureus vaccines for bovine mastitis: a systematic review. Vet Microbiol. 2010; 148(2-4):117-24. DOI: 10.1016/j.vetmic.2010.10.003. View

Stohl W, Elliott J . Differential human T cell-dependent B cell differentiation induced by staphylococcal superantigens (SAg). Regulatory role for SAg-dependent B cell cytolysis. J Immunol. 1995; 155(4):1838-50. View

Tabata Y, Inoue Y, Ikada Y . Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine. 1996; 14(17-18):1677-85. DOI: 10.1016/s0264-410x(96)00149-1. View

Igartua M, Hernandez R, Esquisabel A, Gascon A, Calvo M, Pedraz J . Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J Control Release. 1998; 56(1-3):63-73. DOI: 10.1016/s0168-3659(98)00077-7. View

10.

Chang B, Moon J, Kang H, Kim Y, Lee H, Kim J . Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle. Vaccine. 2008; 26(17):2081-91. DOI: 10.1016/j.vaccine.2008.02.043. View

11.

Brouillette E, Malouin F . The pathogenesis and control of Staphylococcus aureus-induced mastitis: study models in the mouse. Microbes Infect. 2005; 7(3):560-8. DOI: 10.1016/j.micinf.2004.11.008. View

12.

Eldridge J, Staas J, Meulbroek J, Tice T, Gilley R . Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 1991; 59(9):2978-86. PMC: 258122. DOI: 10.1128/iai.59.9.2978-2986.1991. View

13.

Dinges M, Orwin P, Schlievert P . Exotoxins of Staphylococcus aureus. Clin Microbiol Rev. 2000; 13(1):16-34, table of contents. PMC: 88931. DOI: 10.1128/CMR.13.1.16. View

14.

Cui J, Hu D, Lin Y, Qian A, Nakane A . Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. FEMS Immunol Med Microbiol. 2005; 45(1):45-51. DOI: 10.1016/j.femsim.2005.01.010. View

15.

Gupta . Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 2000; 32(3):155-172. DOI: 10.1016/s0169-409x(98)00008-8. View

16.

Ruegg P . Investigation of mastitis problems on farms. Vet Clin North Am Food Anim Pract. 2003; 19(1):47-73. DOI: 10.1016/s0749-0720(02)00078-6. View

17.

Tremaine M, Brockman D, Betley M . Staphylococcal enterotoxin A gene (sea) expression is not affected by the accessory gene regulator (agr). Infect Immun. 1993; 61(1):356-9. PMC: 302730. DOI: 10.1128/iai.61.1.356-359.1993. View

18.

Harro J, Peters B, OMay G, Archer N, Kerns P, Prabhakara R . Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol Med Microbiol. 2010; 59(3):306-23. PMC: 2936112. DOI: 10.1111/j.1574-695X.2010.00708.x. View

19.

Bubeck Wardenburg J, Patel R, Schneewind O . Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun. 2006; 75(2):1040-4. PMC: 1828520. DOI: 10.1128/IAI.01313-06. View

20.

Hu D, Omoe K, Narita K, Cui J, Shinagawa K, Nakane A . Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection. Microbes Infect. 2006; 8(14-15):2841-8. DOI: 10.1016/j.micinf.2006.09.001. View